Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results ... although – following the Capvaxive approval – the CDC's Advisory Committee on Immunisation Practices (ACIP) is ...

The Centers for Disease Control and Prevention (CDC) is scheduled to review ... Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 ...

Many nursing home residents are refusing COVID shots this winter, though flu vaccine penetration has remained strong historically.

The CDC’s Advisory Committee on Immunization ... and that age-targeted approach is central to MSD’s targeted pneumococcal vaccine strategy. It is also deploying its age-targeted serotype ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...

BANDAR SERI BEGAWAN: The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

After the introduction of pneumococcal conjugate vaccine (PCV)-7, emergence of non-PCV7 serotypes, especially 19A, is prominent worldwide, which also contributes to the increase in antimicrobial ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...